Find out how our team of experts at Virtus have helped to investigate the efficacy, safety and pharmacodynamics of a new inhaled immunomodulator.
Pulmotect wanted to generate a comprehensive dataset on the safety, pharmacodynamics and potential efficacy of PUL-042 to inform future trial design in COPD subjects, which was a potential target indication.
Discover how Virtus designed, conducted and analysed a human challenge study.
- 100% successful infection rate
- Demonstrated safety in target population
- Over 30,000 unique data points generated
- New biomarkers identified suggesting a unique mechanism of action